Risk Factors and elsewhere in this Form 10-K. All statements, other than statements of historical facts, included herein that address activities, events or developments that the Company expects or anticipates will or may occur in the future, are forward-looking statements, including statements regarding:  The Companys belief that the current balance of its deferred preservation costs along with its ongoing preservation service activities is sufficient to support its current and projected revenues;  The timing of the discontinuance of HemoStase sales and shipments;  The expected impact of the termination of the Medafor EDA;  Plans and costs related to regulatory approval for the distribution of PerClot in the U.S. and international markets;  Plans and expectations regarding research and development of new technologies and products;  Plans regarding the distribution of BioGlue in Japan, and our estimates regarding the Japanese market for related products and uses;  Strategies to pursue potential acquisition, licensing, or distribution rights of additional technologies that complement our existing services and products;  Plans to expand our core business, develop our pipeline of services and products, and license our technology;  Plans to begin distribution of BioFoam in other international markets, estimates of the aggregate European market opportunity for BioFoam, and expectations regarding clinical trials for BioFoam;  Expected results of the CryoValve SGPV post-clearance study;  Expectations regarding regulatory approval and subsequent shipments of the CryoValve SGAV;  The Companys plans to apply for further federal funding for the development of BioFoam;  The Companys expectations regarding the timing of court rulings in its legal proceedings;  The Companys intentions with respect to lawsuits and the expected impact of current litigation;  Expected benefits of acquisitions;  Anticipated future demand for our tissues and products;  Expectations regarding the impact of healthcare legislation;  The Companys estimated future liability for existing tissue processing and product liability lawsuits and for claims incurred but not yet reported;  Expectations regarding a new credit facility;  Beliefs regarding growth of BioGlue revenues and the factors affecting such growth;  Expectations regarding revenues from PerClot and HemoStase;  Expectations regarding minimum purchase requirements related to PerClot;  The impact of additional HemoStase write-downs or discounts on HemoStase sales;  The impact of expenses associated with lawsuits and business development opportunities;  Managements beliefs that current cardiac and vascular procurement levels are sufficient to support future demand;  The Companys beliefs regarding the seasonal nature of the demand for some of its products and services; 36  The Companys beliefs regarding the rate of decrease of its deferred preservation cost balances;  The adequacy of the Companys financial resources;  The Companys belief that it will have sufficient cash to meet its operational liquidity needs for at least the next twelve months;  The Companys expectations regarding the source of any future payments related to any unreported tissue processing or product liability claims;  Anticipated impact of changes in interest rates and foreign currency exchange rates;  The Companys expectations regarding the renewal of certain contracts;  Expectations regarding the impact of new accounting pronouncements;  Issues that may impact the Companys future financial performance and cash flows; and  Other statements regarding future plans and strategies, anticipated events, or trends. These statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions, and expected future developments as well as other factors it believes are appropriate in the circumstances. However, whether actual results and developments will conform with the Companys expectations and predictions is subject to a number of risks and uncertainties which could cause actual results to differ materially from the Companys expectations, including, without limitation, in addition to those specified in the text surrounding such statements, the risk factors discussed in Item 1A of this Form 10-K and other factors, many of which are beyond the control of CryoLife. Consequently, all of the forward-looking statements made in this Form 10-K are qualified by these cautionary statements, and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequences to or effects on the Company or its business or operations. The Company assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events, or otherwise. 37 Item 1B. Unresolved Staff Comments. The Company has no unresolved written comments received from the staff of the Securities and Exchange Commission regarding its periodic or current reports under the Securities Exchange Act of 1934 not less than 180 days before December 31, 2010 (the end of the fiscal year to which this Form 10-K relates). 